SCHEMBL16777623

SCHEMBL16777623

CC(C)O[P@]1(=O)OC[C@H]2O[C@@H](n3ccc(N)nc3=O)[C@@](F)(Cl)[C@@H]2O1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PDE3A Q14432 3/20 0.41
▸ PDE4D Q08499 1/20 0.41
▸ SLC29A1 Q99808 1/20 0.41
▸ POLA1 P09884 2/20 0.35
▸ POLG P54098 2/20 0.35
▸ LMNA P02545 3/20 0.34
▸ CACNA1F O60840 2/20 0.34
▸ ALB P02768 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ CACNA1D Q01668 2/20 0.34
▸ CACNA1S Q13698 2/20 0.34
▸ CACNA1C Q13936 2/20 0.34
▸ THRB P10828 1/20 0.33
▸ MTOR P42345 1/20 0.33
▸ MDM2 Q00987 1/20 0.33
▸ NCOA1 Q15788 1/20 0.33
▸ NCOA3 Q9Y6Q9 1/20 0.33
▸ FGFR1 P11362 2/20 0.31
▸ POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19107822 1.00 PDE3A (0.41) PDE3APDE4DSLC29A1POLA1POLG
SCHEMBL16777483 1.00 PDE3A (0.41) PDE3APDE4DSLC29A1POLA1POLG
SCHEMBL19107821 1.00 PDE3A (0.41) PDE3APDE4DSLC29A1POLA1POLG
SCHEMBL16777433 1.00 PDE3A (0.41) PDE3APDE4DSLC29A1POLA1POLG
SCHEMBL16777650 1.00 PDE3A (0.41) PDE3APDE4DSLC29A1POLA1POLG
SCHEMBL18270546 0.91 PDE3A (0.47) PDE3APDE4DSLC29A1POLA1POLG
SCHEMBL18263765 0.91 PDE3A (0.47) PDE3APDE4DSLC29A1POLA1POLG
SCHEMBL20222525 0.91 PDE3A (0.47) PDE3APDE4DSLC29A1POLA1POLG
SCHEMBL16777031 0.91 PDE3A (0.38) PDE3APDE4DSLC29A1POLA1POLG
SCHEMBL18270544 0.91 PDE3A (0.47) PDE3APDE4DSLC29A1POLA1POLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170198005-A1 2'-DICHLORO AND 2'-FLUORO-2'-CHLORO NUCLEOSIDE ANALOGUES FOR HCV INFECTION IDENIX PHARMACEUTICALS LLC (US) 2017-07-13 — — US disclosed
US-20170198005-A1 2'-DICHLORO AND 2'-FLUORO-2'-CHLORO NUCLEOSIDE ANALOGUES FOR HCV INFECTION IDENIX PHARMACEUTICALS LLC (US) 2017-07-13 — — US disclosed
WO-2015081297-A1 2'-DICHLORO AND 2'-FLUORO-2'-CHLORO NUCLEOSIDE ANALOGUES FOR HCV INFECTION IDENIX PHARMACEUTICALS, INC. (US) 2015-06-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170198005-A1 2'-DICHLORO AND 2'-FLUORO-2'-CHLORO NUCLEOSIDE ANALOGUES FOR HCV INFECTION HAVCR2, SLC29A2, SLC28A2 PDE3A 2533/4885PDE4D 1849/4885SLC29A1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback